Financials
Cash Data
- Cash FlowProfitable
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
VRTX Catalyst Timeline
Dated clinical, regulatory and corporate events for Vertex Pharmaceuticals Incorporated
Catalyst Timeline
Dated clinical, regulatory & corporate events for Vertex Pharmaceuticals Incorporated
Upcoming catalysts 2
Event history 50
Past FDA Catalysts and PDUFA Decisions
How VRTX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-11-02 | VX-828 | Phase 1 data readout | Phase 1 |
Drug Pipeline Intelligence
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| TRIKAFTA/KAFTRIO | |||
| ALYFTREK | |||
| CASGEVY | |||
| JOURNAVX | |||
| PALSONIFY |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VX-880 BiologicsNCT04786262 | Diabetes Mellitus, Type 1 | Phase 3 | RECRUITING | 57 | Dec 31, 2031 | ||||||
| Povetacicept BiologicsNCT07204275 | Primary Membranous Nephropathy | Phase 2/3 | RECRUITING | 176 | Dec 29, 2028 | ||||||
| Povetacicept BiologicsNCT05732402 | Lupus Nephritis | Phase 1/2 | ACTIVE NOT_RECRUITING | 72 | Mar 2, 2028 | ||||||
| Povetacicept BiologicsNCT07501702 | Myasthenia Gravis, Generalized | Phase 2 | ACTIVE NOT_RECRUITING | 34 | Mar 2, 2029 | ||||||
| Povetacicept BiologicsNCT06564142 | Immunoglobulin A Nephropathy | NDA/BLA | ACTIVE NOT_RECRUITING | 1,250 | Jan 30, 2028 | ||||||
| VX-147 Small MoleculesNCT05312879 | Proteinuric Kidney Disease | Phase 2/3 | ACTIVE NOT_RECRUITING | 522 | May 7, 2030 | ||||||
| Suzetrigine Small MoleculesNCT06696443 | Diabetic Peripheral Neuropathic Pain | Phase 3 | ACTIVE NOT_RECRUITING | 2,289 | Jan 25, 2027 | ||||||
| VX-993 Small MoleculesNCT06619860 | Diabetic Peripheral Neuropathic Pain | Phase 2 | RECRUITING | 300 | Apr 22, 2027 | ||||||
| VX-272 Small MoleculesNCT07437105 | Cystic Fibrosis | Phase 1 | RECRUITING | 160 | Jun 26, 2027 | ||||||
| VX-581 Small MoleculesNCT07813039 | Cystic Fibrosis | Phase 1 | ACTIVE NOT_RECRUITING | 168 | Oct 27, 2026 | ||||||
| VX-407 Small MoleculesNCT07161037 | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Phase 2 | ACTIVE NOT_RECRUITING | 439 | Dec 31, 2027 | ||||||
| 14C-VX-407 Small MoleculesNCT07868926 | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Phase 1 | RECRUITING | 8 | Dec 15, 2026 | ||||||
| VX-433 Small MoleculesNCT07584434 | Narcolepsy Type 1 (NT1) | Phase 1 | RECRUITING | 118 | Mar 5, 2027 | ||||||
| VX-670 RNA-Based TherapiesNCT06185764 | Myotonic Dystrophy Type 1 (DM1) | Phase 2 | ACTIVE NOT_RECRUITING | 91 | Feb 2, 2027 | ||||||
| CTX001 CRISPR-Based Gene Editing TherapiesMarketedNCT05329649 | Sickle Cell Disease | Approved | ACTIVE NOT_RECRUITING | 13 | Jun 6, 2027 | ||||||
| Trikafta Small MoleculesMarketedNCT05331183 | Cystic Fibrosis | Approved | ACTIVE NOT_RECRUITING | 3,323 | Apr 6, 2027 | ||||||
| Alyftrek Small MoleculesMarketedNCT05422222 | Cystic Fibrosis | Approved | ACTIVE NOT_RECRUITING | 2,534 | Jun 30, 2030 | ||||||
| CTX001 CRISPR-Based Gene Editing TherapiesMarketedNCT05356195 | Beta-Thalassemia | Approved | ACTIVE NOT_RECRUITING | 261 | Nov 14, 2027 | ||||||
| Povetacicept BiologicsCompletedNCT05757570 | Idiopathic Thrombocytopenic Purpura | Phase 1/2 | COMPLETED | 30 | Aug 12, 2026 | ||||||
| ALPN-303 Small MoleculesCompletedNCT05034484 | Undisclosed | Phase 1 | COMPLETED | 72 | Feb 27, 2023 | ||||||
| VX-147 Small MoleculesCompletedNCT05955872 | Glomerulosclerosis, Focal Segmental | Phase 2 | COMPLETED | 37 | Sep 2, 2023 | ||||||
| Inaxaplin Small MoleculesCompletedNCT06794996 | Proteinuric Kidney Disease | Phase 2 | COMPLETED | 42 | Jul 20, 2026 | ||||||
| IXP Small MoleculesCompletedNCT06529796 | Focal Segmental Glomerulosclerosis (FSGS) | Phase 1 | COMPLETED | 36 | Dec 20, 2024 | ||||||
| IXP Small MoleculesCompletedNCT05865171 | Renal Impairment | Phase 1 | COMPLETED | 16 | Jun 12, 2024 | ||||||
| Suzetrigine Small MoleculesMarketedNCT07378865 | Pain | Approved | COMPLETED | 387 | Aug 17, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every VRTX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ALYFTREK | cystic fibrosis | Phase 3 | 2026-10-09 | mean FE 1: 239.7 μg/g; mean increase FE 1: 110.2 µg/g; percentage reaching threshold: 48.6%; children discontinued PERT: 18 (37.5%); mean duration PERT discontinuation: 8.6 weeks; range PERT discontinuation: 1.9 to 17.6 weeks; children not on PERT: 50%Read More | Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis ConferenceRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| WAGNER CHARLES F JROfficer (EVP, CO & FO) | Sell | -15,286 31,764 held | $547.87 | 11/12/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in VRTX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TRI LOCUM PARTNERS LP | 13.7 % (11.4 %) | 69.48 M | 132.90 K | -34.14% ( -68.89 K) |
Ownership Trends
VRTX Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How VRTX ranks across every disease it competes in
VRTX News
Vertex to Participate in Upcoming Investor Conferences
Vertex Pharmaceuticals announced participation in three upcoming investor conferences. Key executives will engage in fireside chats at the UBS Global Biopharma Conference, Jefferies Global Healthcare Conference, and Evercore Healthcare Conference in November and December 2026. Live webcasts of these events will be available on the company's website.
Read more →Vertex Reports Third Quarter 2026 Financial Results
Vertex Pharmaceuticals reported a strong third quarter for 2026, achieving total revenue of $3.44 billion, a 12% increase from the previous year. The company raised its full-year revenue guidance to between $13.15 billion and $13.25 billion. Key drivers included robust performance in cystic fibrosis therapies and the successful acquisition of Crinetics Pharmaceuticals. However, GAAP net income saw a decline due to acquisition-related expenses.
Read more →Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026
Vertex Pharmaceuticals announced positive Phase 3 RAINIER results for povetacicept in IgA nephropathy, published in NEJM and presented at ASN Kidney Week 2026. The trial achieved a 52% reduction in proteinuria at Week 36, meeting both primary and secondary endpoints. The FDA's PDUFA date for potential accelerated approval is set for November 30, 2026.
Read more →Vertex Appoints Daniel Brennan to its Board of Directors
Vertex Pharmaceuticals appointed Daniel Brennan to its Board of Directors. Brennan, with over 35 years of finance experience, previously served as CFO at Boston Scientific. His financial leadership is expected to support Vertex's growth and innovation efforts. The Board size increased from 10 to 11 members with this appointment.
Read more →Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference
Vertex Pharmaceuticals announced promising interim data from the ALYFTREK® study, which focuses on children aged 2 to 5 with cystic fibrosis. The data indicates that some children have shown recovery of exocrine pancreatic function, allowing them to stop pancreatic enzyme replacement therapy. This marks a significant advancement in the treatment of cystic fibrosis.
Read more →Vertex to Announce Third Quarter 2026 Financial Results November 2nd
Vertex Pharmaceuticals will announce its third quarter 2026 financial results on November 2, 2026, after market close. A conference call and webcast will follow at 4:30 p.m. ET, providing investors with insights into the company's performance. Access details for the call are provided for both U.S. and international participants.
Read more →Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial
Vertex Pharmaceuticals announced positive results from the Phase 2b AMPLIFIED study of inaxaplin for APOL1-mediated kidney disease. The study demonstrated significant reductions in urine albumin to creatinine ratio (UACR) in patients with modest proteinuria and those with type 2 diabetes. Vertex has completed enrollment in the Phase 2/3 AMPLITUDE trial, with interim analysis results expected in early 2027, which could support accelerated approval in the U.S.
Read more →Vertex Partners With World Champion Skier Lindsey Vonn to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe Acute Pain
Vertex Pharmaceuticals has teamed up with champion skier Lindsey Vonn to promote JOURNAVX, a non-opioid medication approved for treating moderate-to-severe acute pain. This partnership aims to raise awareness about the first new class of pain medicine in over two decades. JOURNAVX was approved by the FDA in January 2025.
Read more →Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team
Vertex Pharmaceuticals has successfully completed its acquisition of Crinetics Pharmaceuticals, a company specializing in therapeutics for endocrine diseases. This acquisition is part of Vertex's strategy to diversify and grow its portfolio. Additionally, the company has expanded its executive leadership team to better support its ongoing development and expansion efforts.
Read more →Vertex to Participate in Upcoming September Investor Conferences
Vertex Pharmaceuticals has announced its participation in four upcoming investor conferences, highlighting its commitment to investor engagement. Senior Vice President Susie Lisa and Executive Director Manisha Pai will lead discussions at notable events, including the Wells Fargo 21st Annual Healthcare Conference. This proactive approach reflects the company's transparency and confidence in its future.
Read more →Vertex Reports Second Quarter 2026 Financial Results
Vertex Pharmaceuticals reported strong financial results for Q2 2026, highlighting significant revenue growth in cystic fibrosis, sickle cell disease, beta thalassemia, and acute pain. The company also updated its full-year revenue guidance positively. Additionally, the pending acquisition of Crinetics will expand its focus to rare endocrine diseases.
Read more →Vertex to Announce Second Quarter 2026 Financial Results on August 3rd
Vertex Pharmaceuticals is set to announce its financial results for the second quarter of 2026 on August 3rd. This announcement is part of the company's regular financial reporting schedule. Details regarding the performance and outlook will likely be discussed during the announcement.
Read more →Vertex to Acquire Crinetics Pharmaceuticals
Vertex Pharmaceuticals has announced its intention to acquire Crinetics Pharmaceuticals. The acquisition aims to enhance Vertex's portfolio and capabilities in the biopharmaceutical sector. Further details regarding the financial aspects and strategic implications of the acquisition have yet to be disclosed.
Read more →Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia
Vertex has received FDA approval for the expanded use of CASGEVY® in treating individuals aged 2 and older with sickle cell disease or transfusion-dependent beta thalassemia. This approval represents a significant milestone in providing effective treatment options for these conditions. The decision is expected to enhance patient care and outcomes.
Read more →Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions
Vertex Pharmaceuticals presented new data on CASGEVY® at the European Hematology Association Congress. This included the first European presentation of data in children aged 5-11. Additionally, the company announced further global regulatory submissions related to CASGEVY®.
Read more →Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference
Vertex Pharmaceuticals presented new data on ALYFTREK® at the European Cystic Fibrosis Conference. The details of the findings were not disclosed in the article. The presentation is expected to contribute to ongoing discussions about cystic fibrosis treatments.
Read more →Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10
Vertex Pharmaceuticals will participate in the Goldman Sachs 47th Annual Global Healthcare Conference scheduled for June 10. This event is a significant platform for the company to engage with investors and discuss its strategic initiatives. Further details about the participation are yet to be disclosed.
Read more →Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy
Vertex Pharmaceuticals announced that the U.S. FDA has accepted its Biologics License Application for Povetacicept, aimed at treating IgA Nephropathy. This acceptance is a crucial step towards potential accelerated approval, which may enhance patient access to this innovative therapy. The company is optimistic about the drug's prospects in addressing this condition.
Read more →Vertex to Participate in Upcoming May 2026 Investor Conferences
Vertex Pharmaceuticals announced its participation in two upcoming investor conferences in May 2026. The company is known for its innovative therapies for serious diseases and has a strong clinical pipeline. Vertex has been recognized as a top employer, reflecting its commitment to workplace excellence.
Read more →Vertex to Participate in Upcoming May Investor Conferences
Vertex Pharmaceuticals is set to participate in several investor conferences in May. The details regarding the specific conferences and the topics to be discussed have not been disclosed. This participation may provide insights into the company's future plans and developments.
Read more →